These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28256984)

  • 1. Abstracts from the 3rd International PPRI Conference 2015: Pharmaceutical Pricing and Reimbursement Policies: Challenges Beyond the Financial Crisis.
    Vogler S; Zimmermann N; Ferrario A; Wirtz VJ; Babar ZUD
    J Pharm Policy Pract; 2015 Oct; 8 Suppl 1(Suppl 1):E1-P29. PubMed ID: 28256984
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference.
    Vogler S; Zimmermann N; Ferrario A; Wirtz VJ; de Joncheere K; Pedersen HB; Dedet G; Paris V; Mantel-Teeuwisse AK; Babar ZU;
    J Pharm Policy Pract; 2016; 9():9. PubMed ID: 26981252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical policies in European countries in response to the global financial crisis.
    Vogler S; Zimmermann N; Leopold C; de Joncheere K
    South Med Rev; 2011 Dec; 4(2):69-79. PubMed ID: 23093885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference.
    Vogler S; Zimmermann N; Babar ZU; Busse R; Espin J; Mantel-Teeuwisse AK; Panteli D; Suleman F; Wirtz VJ
    J Pharm Policy Pract; 2021 Jan; 14(1):18. PubMed ID: 33494798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European pharmaceutical pricing and reimbursement conference.
    Ehreth J; Williams D
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):37-9. PubMed ID: 19371177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK.
    Ogbighele E
    IDrugs; 2010 May; 13(5):317-20. PubMed ID: 20432188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
    Castillo-Laborde C; Silva-Illanes N
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abstracts from the 3rd International PPRI Conference, October 12-13, 2015, Vienna, Austria.
    Hill SR
    J Pharm Policy Pract; 2015; 8 Suppl 1(Suppl 1):K1-P29. PubMed ID: 26468394
    [No Abstract]   [Full Text] [Related]  

  • 10. PRICING, REIMBURSEMENT, AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINAL PRODUCTS IN BULGARIA.
    Benisheva-Dimitrova T; Sidjimova D; Cherneva D; Kralimarkov N
    Int J Technol Assess Health Care; 2017 Jan; 33(3):365-370. PubMed ID: 28831942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in external price referencing in Europe: a descriptive overview.
    Leopold C; Vogler S; Mantel-Teeuwisse AK; de Joncheere K; Leufkens HG; Laing R
    Health Policy; 2012 Jan; 104(1):50-60. PubMed ID: 22014843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region.
    Chen Y; Schweitzer SO
    Value Health; 2008 Mar; 11 Suppl 1():S124-9. PubMed ID: 18387056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pricing of pharmaceuticals: an international comparison.
    Dickson M
    Clin Ther; 1992; 14(4):604-10; discussion 603. PubMed ID: 1525794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical reference prices. How do they work in practice?
    Dickson M; Redwood H
    Pharmacoeconomics; 1998 Nov; 14(5):471-9. PubMed ID: 10344913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review.
    Kawalec P; Tesar T; Vostalova L; Draganic P; Manova M; Savova A; Petrova G; Rugaja Z; Männik A; Sowada C; Stawowczyk E; Harsanyi A; Inotai A; Turcu-Stiolica A; Gulbinovič J; Pilc A
    Front Pharmacol; 2017; 8():892. PubMed ID: 29326583
    [No Abstract]   [Full Text] [Related]  

  • 19. Pricing and reimbursement of pharmaceuticals in Portugal.
    Gouveia Pinto C; Teixeira I
    Eur J Health Econ; 2002; 3(4):267-70. PubMed ID: 15609153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of alternative medicare reimbursement policies under optimal hospital pricing.
    Dittman DA; Morey RC
    Health Serv Res; 1983; 18(2 Pt 1):137-64. PubMed ID: 6347973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.